ALPMF (Astellas Pharma) Other Current Assets: $334 Mil (As of Mar. 2026)


ALPMF Astellas Pharma Inc ALPMF
73 GF Score
Price $14.15
GF Value $14.60
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Other Current Assets?

Astellas Pharma ALPMF 73 Other Current Assets is $334 Mil as of Mar. 2026. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.60 (Fairly Valued). The stock has 4 warning signs investors should review.

Astellas Pharma's other current assets for the quarter that ended in Mar. 2026 was $334 Mil.

Astellas Pharma's quarterly other current assets declined from Sep. 2025 ($407 Mil) to Dec. 2025 ($357 Mil) and declined from Dec. 2025 ($357 Mil) to Mar. 2026 ($334Mil).

Astellas Pharma's annual other current assets increased from Mar. 2024 ($311 Mil) to Mar. 2025 ($357 Mil) declined from Mar. 2025 ($357 Mil) to Mar. 2026 ($334 Mil).


Astellas Pharma Other Current Assets Related Terms


Astellas Pharma Other Current Assets Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Other Current Assets Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 426.19 381.40 310.62 357.24 333.52

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 357.24 453.80 406.59 356.67 333.52
ALPMF
73GF Score
Astellas Pharma Inc ALPMF
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $334 Mil mean?
Astellas Pharma (ALPMF) has a Other Current Assets of $334 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Astellas Pharma.
Is Astellas Pharma's Other Current Assets too high?
Astellas Pharma's current Other Current Assets is $334 Mil. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Other Current Assets compare to LLY and JNJ?
Astellas Pharma's Other Current Assets of $334 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Astellas Pharma. Astellas Pharma's current Other Current Assets is $334 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.60, compared to a current price of $14.15 — trading 3.1% below its estimated fair value. The current Other Current Assets is $334 Mil. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Other Current Assets is $334 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $14.15 is trading 3.1% below its estimated GF Value™ of $14.60. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • Other Current Assets: $334 Mil
  • GF Value™: $14.60 vs. price of $14.15 (3.1% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score

Get the complete analysis for ALPMF

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.15
Price
$14.60
GF Value